







Service	Why? (Purpose)	Who? (Design for)	What? (Tested Gene)	When? (Turnaround Time)	How?(Sample Requirement)
 <p>ACTRisk™</p>	Preventive screening and detects inherited driver mutations	<ul style="list-style-type: none"> • Individuals with family history of early-onset cancer • An individual with multiple primary cancers • An individual with rare cancer • Individuals who are health-conscious 	Sequencing 32 hereditary cancer related genes	30 Calendar days	<ul style="list-style-type: none"> • Whole blood (PBMC) • Buccal swab
 <p>ACTBRCA™</p>	Analyzing BRCA1/2 exons and detects somatic and germline mutations	<ul style="list-style-type: none"> • Breast Cancer Patients • Ovarian Cancer Patients • Prostate Cancer • Patients Pancreatic Cancer Patients • Individuals with family history of breast, ovarian or other BRCA1/2 mutations related cancer 	Sequencing of all BRCA1/2 exons	14 Calendar days	<ul style="list-style-type: none"> • FFPE • Whole blood (PBMC for germline mutation test)
 <p>ACTOnco®+</p>	Comprehensive genomic profile and recommendations of targeted drugs	<ul style="list-style-type: none"> • Patients with solid tumors • Patients who wish to test for target therapy evaluation. • Patients who suffer from relapse or metastasis. • Patients who need to explore new treatment options. 	Comprehensive profiling genomic profiling for more than 400 cancer-related genes	14 Calendar days	<ul style="list-style-type: none"> • FFPE • Core needle biopsy • Frozen tissue • Pleural effusion • Ascites samples • Purified DNA
 <p>ACTDrug®+</p>	Providing tailored drug options	<ul style="list-style-type: none"> • Patients who are newly diagnosed with cancer • Patients who are evaluating targeted therapy treatment 	Genomic profiling for 35 druggable genes	14 Calendar days	<ul style="list-style-type: none"> • FFPE • Core needle biopsy • Frozen tissue • Pleural effusion • Ascites samples • Purified DNA
 <p>ACTImmune™</p>	Predict the feasibility of immunotherapy	<ul style="list-style-type: none"> • Patients who want to use immune checkpoint inhibitors • Patients who wish to predict response for immunotherapy 	Analyzing more than 18,000 genes for neoantigen prediction	30 Calendar days	<ul style="list-style-type: none"> • FFPE • Frozen tissue • Whole blood (PBMC)
 <p>ACTMonitor™</p>	Monitoring of cancer recurrence and drug resistance	<ul style="list-style-type: none"> • Patients with solid tumor unsuitable for surgery • Patients with solid tumor and have developed drug resistance • Patients with solid tumor and risk of cancer recurrence • Patients with solid tumor and wish to monitor treatment response 	Sequencing from 8-50 genes (optionable panels for specific cancer types)	14 Calendar days	Whole blood (Plasma)